|
FTC Conditions on Watson’s Actavis Acquisition Are Manageable: Analyst
The FTC tentatively approved Watson Pharmaceuticals’ acquisition of Actavis, provided Watson transfers rights to 18 drugs to Sandoz and Par Pharmaceuticals and relinquishes manufacturing and marketing rights to three other products involved in the sale.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives